Clarithromycin

Generic Name: Clarithromycin

Brand Names: Biaxin, Biaxin Bid, Omeclamox, Prevpac, Voquezna 14 Day Triplepak 20;500;500

Drug Type: Small Molecule

Chemical Formula: C_₃₈H_₆₉NO_₁₃

CAS Number: 81103-11-9

Unique Ingredient Identifier: H1250JIK0A

Background: Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bacteri...

Indication: An alternative medication for the treatment of acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity. Also for the treatment of pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, as well as respiratory tract infections including acute maxillary sinu...

Associated Conditions: Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), Acute maxillary sinusitis, Bacterial Infections, Bartonellosis, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Helicobacter Pylori Infection, Infective Endocarditis (IE), Lyme Disease, Mycobacterial Infections, Otitis Media (OM), Pertussis, Streptococcal Pharyngitis, Tonsillitis streptococcal, Uncomplicated skin and subcutaneous tissue bacterial infections

Associated Therapies: -

Clinical Trials

A Study to Evaluate the Effect of Clarithromycin on LY2216684

Phase 1

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: LY2216684
Drug: Clarithromycin

First Posted Date: 2011-10-26

Last Posted Date: 2018-10-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 14

Registration Number: NCT01460407

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

Phase 1

Completed

Conditions: Nonhematologic Malignancies
Lymphoma

Interventions: Drug: Ixazomib 2.5 mg
Drug: Ixazomib 4 mg Capsule A
Drug: Rifampin
Drug: Ixazomib 4 mg Capsule B
Drug: Ketoconazole
Drug: Clarithromycin

First Posted Date: 2011-10-18

Last Posted Date: 2017-11-01

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 112

Registration Number: NCT01454076

Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Tadalafil
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Clarithromycin

First Posted Date: 2011-06-15

Last Posted Date: 2018-12-10

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 14

Registration Number: NCT01374217

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Efficacy of Clarithromycin Treatment in Prevention of Chronic Lung Disease in Premature Infants

Phase 4

Completed

Conditions: Chronic Lung Disease

Interventions: Drug: Clarithromycin
Drug: Dextrose

First Posted Date: 2011-03-31

Last Posted Date: 2011-03-31

Lead Sponsor: Zekai Tahir Burak Women's Health Research and Education Hospital

Target Recruit Count: 273

Registration Number: NCT01326611

Locations: 🇹🇷
Zekai Tahir Burak Maternity Teaching Hospital Neonatology department, Ankara, Turkey

Treatment of Mycobacterium Xenopi Pulmonary Infection

Phase 3

Completed

Conditions: Atypical; Mycobacterium, Pulmonary, Tuberculous

Interventions: Drug: Clarithromycin
Drug: Moxifloxacin

First Posted Date: 2011-02-17

Last Posted Date: 2020-07-20

Lead Sponsor: Centre Hospitalier Universitaire, Amiens

Target Recruit Count: 92

Registration Number: NCT01298336

Locations: 🇫🇷
CH Béthune, Béthune, France
🇫🇷
CHU Besançon, Besançon, France
🇫🇷
CH Abbeville, Abbeville, France

and more 49 locations

Clarithromycin as Immunomodulator for the Management of Sepsis

Phase 3

Completed

Conditions: Septic Shock
Severe Sepsis
Sepsis

Interventions: Drug: Dextrose 5%
Drug: Clarithromycin

First Posted Date: 2010-10-19

Last Posted Date: 2011-08-04

Lead Sponsor: University of Athens

Target Recruit Count: 600

Registration Number: NCT01223690

Locations: 🇬🇷
2nd Department of Surgery, University of Thessaloniki, Thessaloniki, Greece
🇬🇷
2nd Department of Medicine, Sismanogleion General Hospital, Athens, Greece
🇬🇷
4th Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece

and more 3 locations